The Computer-Administered Neuropsychological Screen
for Mild Cognitive Impairment
Easily assess your patient’s cognitive health.
Gain higher reimbursements with the CANS-MCI.
Preclinical Diagnosis of ADBiomarker research finds CANS-MCI performance predicts both elevated Aβ and tau. The CANS-MCI captures item-level response times at millisecond accuracy and can detect patterns of delay associated with the preclinical stage of AD. To read more about this research, click here.
Concussion AssessmentThe central changes in cognitive ability due to sports concussion are memory, cognitive processing speed, and reaction time — all measured at millisecond accuracy by the CANS-MCI. Our automated administration also eliminates the potential for either the deliberate or unintended bias of in-person testers. Comparison to baseline can be performed before risking a second concussion.
A Complement to New TherapiesWith the introduction of new therapies that promise to slow Alzheimer’s disease, early detection of mild cognitive impairment is more important than ever. Accurate, affordable, and validated screening measures such as the CANS-MCI have an important role to play. Detecting pre-symptomatic changes in cognition can help doctors assess the need for patient biomarker testing.
Tracking Cognitive HealthThe earlier your patients receive intervention to slow, stop, or reverse cognitive decline, the more likely treatments are to be successful and their cognitive health preserved. The CANS-MCI meets this need for affordable baseline and precise longitudinal tracking. It compares with gold standard neuropsychological exams at a tiny fraction of the cost.
Eight distinct tests administered in a single session.
- Wechsler Memory Scale-Revised (WMS-R)
- Logical Memory Immediate and Delayed (LMS-I and LMS-II)
- Mattis Dementia Rating Scale (DRS)
- Wechsler Adult Intelligence Scale, Digit Symbol test
- (Later validated against the MOCA and MMSE)
- (Later correlated with CSF amyloid β 1-42 (Aβ) and tau levels)